Arctoris brings together a world-class team and a revolutionary technology platform.

Our mission

Arctoris is a tech-enabled drug discovery company headquartered in Oxford and Boston. Arctoris combines its unique automation platform, Ulysses, with advanced computational approaches and a world-class team of seasoned drug hunters to guide and rapidly progress its wholly owned and partnered drug discovery programs in oncology and neurology.

With millions suffering from chronic illnesses, the world continues to be in desperate need of new and better therapies to improve and extend lives. This is why we are here: we combine a world-class team with a unique integrated technology architecture to drive our mission to revolutionize drug discovery and accelerate the development of new medicines. Better data today will lead to better drugs tomorrow.

Read more about team, technology, and your future with us below.

Our team

Our global team consists of biotech and pharma veterans, robotics and machine learning engineers, as well as seasoned life sciences executives. Together, we challenge conventions in drug discovery, and relentlessly pursue a data-first approach to find and develop new drugs faster. We are driven by our mission to revolutionize drug discovery and accelerate science.

Co-founder and CEO

THOMAS A. FLEMING

Co-founder and COO

Scientific Advisor

Scientific Advisor

BETH J. HOFFMAN

 Board Advisor

DANIEL THOMAS

Head of Discovery Biology

VISHAL GULATI

Chairman of the Board

Scientific Advisor

POPPY ROWORTH

VP Operations

Steven Holtzman

Board Advisor

SALLY CULLEN

Chief People Officer

SIR MICHAEL BRADY OBE

Scientific Advisor

PATRICK PICHETTE

Board Advisor

Professor Khusru Asadullah

Scientific Advisor

Stanley Lapidus

Board Advisor

Meet Ulysses

Drug discovery is a series of decision-making steps, driven by data. We developed Ulysses, a unique platform that brings together robotics, data science, and machine learning to make better decisions based on data of unprecedented quality, depth and context, at scale.

With Ulysses, we enable the right decisions at the right time, reducing cycle times, decreasing attrition rates, and significantly improving drug discovery success rates. Our platform powers our internal discovery work, and is also accessible to select partners, enabling them to accelerate their programs from idea to IND, bringing new medicines to patients faster.

Our investors

And a group of truly exceptional angel investors.

Our values

We are always looking for our next Arctorian. At Arctoris, we value absolute integrity and trust among our team and our clients. We champion the data, focus on delivering the best-possible data quality, and always ask “how could this be done better?”. We share an obligation to dissent among a strong, mission-driven, diverse team, and we never let a team member fail.

Arctoris is growing. Come join us.

Open roles

There are no open roles at this time, please check back soon.

Martin-Immanuel Bittner

Co-founder and CEO

Martin completed his medical degree in Germany and his DPhil in Oncology as a Rhodes Scholar at the University of Oxford. He worked in both clinical trials and drug discovery, is a member of AACR, EACR and ESTRO, actively involved in the Open Science movement, and in 2018 was elected a member of the Young Academy of the German National Academy of Sciences in recognition of his research achievements.

THOMAS A. FLEMING

Thomas A. Fleming

Co-founder and COO

Tom is a Royal Academy of Engineering SME Leader and was formerly a cancer researcher and Fellow of the Royal Commission of 1851 at the University of Oxford. A chemist by background, he worked both at leading CROs and pharmaceutical corporations. Tom has unique insights into drug discovery, including the critical steps from target identification & validation to high-throughput screening & lead optimization.

John Davis

Scientific Advisor

John Davis is the Chief Scientific Officer of the Centre for Medicines Discovery (Oxford) and Director of Business Development for the Alzheimer’s Research UK – Drug Discovery Alliance. He has over 25 years of drug discovery expertise all the way from target identification to successful clinical proof of concept for a range of drug candidates in neurological disorders. Following postdoctoral training at the Ludwig Institute and the Salk Institute, he joined GlaxoSmithKline where he led a variety of non-clinical pharmacology research departments for pain and neurodegenerative diseases. In 2010, Professor Davis co-founded the spinout company Convergence Pharmaceuticals, which he later left to become Director of Discovery for Selcia, and CSO and cofounder of Cypralis before joining the University of Oxford.

Rafael Gómez Bombarelli

Scientific Advisor

Rafael Gómez Bombarelli is the Jeffrey Cheah Assistant Professor in Engineering in MIT’s Department of Materials Science and Engineering. His research is focused on accelerated discovery cycles and machine learning approaches for molecular design and optimisation. Professor Gómez Bombarelli’s work has been published in journals such as Science, Nature Chemistry, and Nature Materials, and has been featured in MIT Technology Review and Wall Street Journal. He earned a BS, MS and PhD in chemistry from the Universidad de Salamanca, followed by postdoctoral work at Heriot-Watt University, Harvard University and Kyulux North America before taking up his post at MIT.

BETH J. HOFFMAN

Beth J. Hoffman

Advisory Board Member

Beth Hoffman PhD is a seasoned pharmaceutical and biotech executive. Beth is the CEO of San Diego-based Origami Therapeutics. During her distinguished career she has also served as Vice-President of Discovery Biology at Vertex Pharmaceuticals and held leadership positions at Amgen, Eli Lilly, and the NIH. Beth brings invaluable experience in drug
discovery and development, both from the R&D and business perspective.

DANIEL THOMAS

Daniel Thomas

Head of Discovery Biology

Dan received his BSc and PhD from the University of Leeds before joining GlaxoSmithKline, where he spent 20 years working in small molecule drug discovery directing teams in target identification and validation. At Arctoris, Dan leads the implementation of a comprehensive scientific strategy designed to deliver high-quality, reproducible and richly annotated data sets.

VISHAL GULATI

Vishal Gulati

Chairman of the Board
Vishal is an MD PhD and partner at one of Europe’s leading venture capital firms, DraperEsprit, leading their investments in the digital health and drug discovery space. He is also a board member of Horizon Discovery, Fluidic Analytics, and EcoEos. Vishal is a Rhodes Scholar and Chairman of the Digital Health Forum. Before joining DraperEsprit, Vishal worked at Atlas Ventures and the Wellcome Trust.

Teodoro Laino

Scientific Advisor

Teodoro Laino leads the chemical computation and automated synthetic chemistry efforts at the Department of Cognitive Computing and Industry Solutions at the IBM Research Zurich Laboratory. He is interested in the application of machine learning to chemistry and materials science problems with the purpose of developing scalable, tech-enabled solutions to significantly improve chemical synthesis (e.g., IBM RXN for chemistry). A chemist by background, Dr Laino has a PhD in computational chemistry, after which he worked as a post-doctoral researcher at the University of Zurich developing algorithms for molecular dynamics simulation.

POPPY ROWORTH

Poppy Roworth

Head of Laboratory
Poppy completed her DPhil in Oncology at the University of Oxford and her BSc in Biochemistry at the University of Southampton. She worked for AstraZeneca in the Oncology iMED unit, employing robotic systems for drug discovery. Poppy also was a Visiting Researcher at OncoRay-Dresden. She actively promotes women in STEM and has won several awards as a biochemist.
Steven Holtzman

Steven Holtzman

Board Advisor

Steven is an internationally recognized leader in the biopharma space. He was the CEO of Decibel Therapeutics, CEO & Founder of Infinity Pharmaceuticals, Chief Business Officer of Millennium Pharmaceuticals, and also served as EVP of Corporate Development at Biogen. Steven advises the board on business strategy, the commercial and competitive landscape, and asset-based value-generation.

SALLY CULLEN

Sally Cullen

Chief People Officer

Sally brings a wealth of knowledge and experience to Arctoris. Her passion for people and development ensures we continue to invest in our ambitious talent and culture agenda. Sally has diverse experience in building high performance teams in high growth tech companies. She has been a member of the Chartered Institute for Personnel & Development for over 20 years and is a qualified occupational psychologist.

SIR MICHAEL BRADY OBE

Sir Michael Brady OBE

Advisory Board Member

Professor Brady FRS FREng FMedSci FIET FInstP FBCS is a Professor of Information Engineering and a Professor of Oncology at the University of Oxford. He was awarded the Faraday medal and seven honorary doctorates, founded MIT’s robotics laboratory, and co-founded eight startups. He advises the board of Arctoris on technological development and strategy in biomedicine.
PATRICK PICHETTE

Patrick Pichette

Board Advisor
Patrick is a general partner at leading Canadian venture capital firm Inovia Capital, heading their London office. He is also the chairman of Twitter, board member of the Trudeau Foundation, and an active angel investor. Previously, he was Senior Vice President and CFO of Google, CFO of Bell Canada, and partner at McKinsey. He advises the board of Arctoris on its growth and financial strategy.
Professor Khusru Asadullah

Professor Khusru Asadullah

Advisory Board Member

Professor Asadullah is an expert in translational medicine and former Vice-President & Head of Target Discovery at Bayer. He spent more than 15 years as pharma executive, authored 160 publications and led the industry-changing Bayer reproducibility study. Professor Asadullah advises the board on translational and precision medicine, data standards, and drug discovery best practices.

Stanley Lapidus

Stanley Lapidus

Advisory Board Member

Stan is a highly successful biotech and medtech entrepreneur and life sciences pioneer with over 30 granted patents. He took two companies from foundation to NASDAQ: EXACT Sciences (EXAS) and Cytyc Corporation (CYTC), bought by Hologic for $6.2 billion. Stan holds an academic appointment at MIT and advises the board on business strategy and the regulatory environment.